Summary of PROCEPT BioRobotics FY Conference Call Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Devices, specifically focused on urology and BPH (Benign Prostatic Hyperplasia) treatments Key Points and Arguments 1. Q1 and 2026 Guidance - The company expects procedure volumes to build throughout the year, with foundational changes made to the sales force to enhance effectiveness in launches [2][3] - The guidance for Q1 reflects a cautious approach, factoring in near-term headwinds but anticipating benefits in the latter half of the year [5] 2. Inventory Management - Historical inventory levels were around 115% compared to procedure volumes, now optimized to a 1:1 ratio, which is expected to be maintained [6][10] - The company has observed improved alignment between handpiece sales and procedure volumes, indicating a more stable inventory equilibrium [10][12] 3. Launch Team Structure - A new launch team structure has been implemented to improve the efficiency of system placements and ensure successful launches [17][28] - The goal is for over half of the systems launched in 2026 to operate under this new model, which is expected to enhance overall system utilization [27][28] 4. Changes in Incentive Plans - The incentive plans for the utilization team have been simplified to focus on productivity rather than behaviors, aiming to drive performance and accountability [30][31] - Feedback from the sales team has been positive, with enthusiasm noted during the sales meeting [31][35] 5. Reimbursement Strategy - The transition from Category 3 to Category 1 coding has been a significant development, with the company ensuring proper coding to avoid reimbursement issues [44] - The APC level has increased by 5%, indicating a positive trend in reimbursement support [44] 6. Capital Revenue and System Placements - Projected capital revenue for 2026 is estimated between $95 million and $100 million, with system placements expected to remain flat compared to 2025 [45][49] - A replacement strategy for older systems is being developed, which may include trade-in credits for existing systems [50][51] 7. Market Penetration and Patient Awareness - The company aims to convert competitive procedures to its own, targeting a market of 400,000 patients annually, with only 10% penetration currently [61] - There is a significant opportunity to educate patients about the benefits of their procedures, as many are unaware of alternatives to traditional treatments [75] 8. Future Opportunities - The company is exploring operational leases to facilitate access to technology for hospitals that may not want to make capital purchases [52] - There is a focus on expanding indications for localized prostate cancer treatments, with ongoing trials expected to yield data in the near future [65][66] Additional Important Insights - The company has noted that the utilization of the HYDROS system is higher compared to the AquaBeam, attributed to its ease of use and integrated features [58] - There is a need for ongoing marketing efforts to change patient perceptions regarding BPH procedures, emphasizing the safety and effectiveness of their offerings [63][72] This summary encapsulates the key insights and strategic directions discussed during the PROCEPT BioRobotics FY Conference Call, highlighting the company's focus on growth, operational efficiency, and market education.

PROCEPT BioRobotics 2026 Investor Day Summary Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically focused on urology and BPH (Benign Prostatic Hyperplasia) treatment Key Points and Arguments Market Opportunity - Approximately **400,000 patients** undergo prostate procedures annually, with only **10% market penetration** by PROCEPT, indicating significant growth potential [2][3] - There are **8 million men** seeking therapy for BPH, many dissatisfied with current drug treatments [2] - Over **1 million men** discontinue medication annually due to ineffectiveness or side effects, presenting an additional opportunity [3] Technology and Clinical Evidence - PROCEPT has developed a **game-changing technology** for BPH treatment, with over **125,000 patients** treated and **900 instruments** installed globally [4][5] - The company emphasizes the importance of clinical evidence and aims to demonstrate effective execution in the field to drive market share [4] Reimbursement and Pricing Strategy - Transitioned to **Category I reimbursement** on January 1, 2026, which enhances the narrative around reimbursement and reduces previous uncertainties [5] - Handpiece pricing has seen a **$300 increase**, with expectations for **average selling price (ASP)** to reach **$3,500** in 2026 [11] Revenue Management - Eliminated end-of-quarter volume discounts to stabilize revenue and improve ASP, leading to more predictable ordering patterns [8][9] - Anticipates a **1-to-1 ratio** of handpiece sales to procedures, which is a conservative estimate given the addition of **200+ systems** in 2026 [13][14] Sales Organization Changes - Integrated clinical and sales support teams under a single regional leader to optimize resource allocation and improve performance [15][17] - Aimed to reduce the time from purchase order to first procedures by **50%** through better coordination [21] Strategic Focus Areas 1. **Accelerating Procedure Growth**: Targeting the **10% penetration** in the surgical market and increasing awareness of Aquablation therapy [54][56] 2. **Path to Profitability**: Emphasizing the need for a clear path to profitability and improved margins [4][10] 3. **Advancing Evidence and Innovation**: Continuing to invest in clinical evidence and exploring new indications, including prostate cancer treatment [45][46] Patient-Centric Approach - Highlighting the importance of preserving **urinary and sexual function** while providing effective symptom relief [34][42] - Addressing the misalignment between physician assumptions and patient desires regarding BPH treatment [63][64] - Developing targeted patient education initiatives to increase awareness and understanding of Aquablation therapy [68] Competitive Landscape - Positioning Aquablation as a superior alternative to traditional TURP procedures, which have been around for over **100 years** [31] - Emphasizing the unique benefits of Aquablation, including reduced complications and better long-term outcomes compared to other therapies [30][43] Future Growth Opportunities - Exploring leasing pilot programs to attract customers hesitant about capital expenditures [29] - Anticipating significant growth in the prostate cancer treatment market, leveraging existing technology and expertise [45][49] Additional Important Insights - The company is committed to educating both patients and clinicians about the benefits of Aquablation, aiming to shift perceptions and increase adoption [56][67] - The focus on **durability** and **long-term outcomes** is critical, as many contemporary BPH therapies struggle to maintain market momentum due to lack of sustained effectiveness [62] This summary encapsulates the key insights and strategic directions discussed during the PROCEPT BioRobotics 2026 Investor Day, highlighting the company's growth potential, innovative technology, and commitment to patient-centered care.

Core Insights - Intuitive Surgical (ISRG) stock has increased by 32.4% over the past three months, currently trading at $592.85, just 3.8% below its all-time high of $616 reached in February 2025, reflecting strong investor confidence following robust third-quarter earnings [1][19] Financial Performance - ISRG has outperformed peers like Medtronic (MDT) and PROCEPT BioRobotics (PRCT) in the past three months, with MDT gaining 2.5% and PRCT declining by 0.1% [2] - Total worldwide procedures grew by 20% year over year, driven by a 19% increase in da Vinci procedures and a 52% increase in Ion procedures [2][7] Growth Drivers - Procedure growth is a key component of Intuitive Surgical's long-term value creation, with strong performance noted across various geographies and specialties, including U.S. benign general surgery and international growth in general surgery, gynecology, colorectal, and thoracic procedures [3] - Average system utilization increased by 4% for da Vinci multiport, 35% for SP, and 14% for Ion, indicating rising throughput within the installed base [4] Product Development - The launch of da Vinci 5 is a significant catalyst for revenue growth, with 240 systems placed in Q3, bringing the global installed base to 929 systems [5][7] - Approximately 85% of ISRG's revenues come from recurring sales, supported by features and upgrades of da Vinci 5 [7][9] Competitive Landscape - Rising competition in surgical robotics includes Medtronic's Hugo platform and Procept BioRobotics' AI-powered HYDROS system, which could impact Intuitive Surgical's market dominance [14][16] Future Outlook - Estimates for Intuitive Surgical's 2025 earnings have increased by 8.5% to $8.65 per share, indicating bullish sentiment [17] - Sustained procedure growth, rising utilization, and accelerating da Vinci 5 adoption position the company for durable growth into 2026 [20]